Record quarter validates momentum, but inventory gains muddy near-term clarity

Revenue ₹315.7 Cr (+44.8% YoY), PAT ₹26.1 Cr (+59.6% YoY), OPM 10.6%, NPM 8.27%

EBITDA stated as ₹36.3 Cr = 11.5% margin. Calculation verified: 36.3/315.6 = 11.5%

Revenue grew 44.8% YoY; CFO later clarified mid-teens volume growth. Remainder is commodity price appreciation (zinc up 6–7% QoQ)

Management refused quantification, citing 'small amount.' With zinc prices volatile, gains likely non-recurring

Stated but not independently verified. Helps justify claim of room for volume ramp before new capacity

FY28 target now 50–60% (was 65–70% prior call) due to Q3 FY27 commissioning vs H1 plan. Cited 'conservative approach' but delays revenue/margin ramp by ~2 quarters

Long-term guidance inched to 14–15% from prior 13–14%, driven by stronger product mix (pharma, ceramics) and two new high-margin products (ZRA, LabPure). Dependent on Dahej & non-rubber ramp

Management now explicitly targeting non-rubber segments (pharma 1–3 month approvals vs tire 5 years). Positioned as 40% of Dahej mix vs 18% current base

JG TUR expected to reach commercial scale within 12 months from call date (Aug 2026), replacing '2–3 quarters' prior vagueness. Upside if tire ESG tailwind materializes

Early 80s utilization; double-digit volume growth across categories. Later clarified mid-teens volume; rest is commodity price appreciation (zinc up)

Small amount of inventory gains; margin driven by operating leverage, higher-priced orders, and specialized applications. Refused quantification

November 2026 is good estimate

Already seeding ~1 year; approvals 1–3 months (vs. tire 5 years). Customers aware and establishing relationships; expect quick ramp post-commission

This is the new normal; commodity prices unlikely to fall near-term. New normal for realizations going forward

FY27 (3–4 months): low utilization. FY28: 50–60% minimum. FY29: 70–80%, then Phase 2 expansion

Yes. Stronger products, new R&D output expected to drive higher realization, hence higher EBITDA %

Payback 3–4 years (target across capex). ROCE mid-20s (20–25% annual return needed for 4-year payback)

~5,000 tons added. Exact capex to be provided offline (utilities/capabilities built over years; phased spend)

Neutral to zinc prices (3,000–3,600 range doesn't matter). Cost pass-through assumed

Rubber/tire remain core; but Indian market growing in pharma, ceramics, specialty chemicals. Gujarat facility positioned for 40% non-rubber mix; non-rubber will grow faster than tire going forward

Q1 FY27: ~18%. Exact prior-quarter figure not available; gradually increasing YoY

Mix of factors: operating leverage, higher-margin orders, small inventory gains, cost initiatives (sustainable 3-month push during geopolitical crisis)

Pilot successful, customers happy. Expect commercial start within 12 months from call (Aug 2026). Full capex/timeline to be shared later. ESG tailwind expected from tire industry

Tire ~60%, others (ceramics, agri, specialty chemicals) ~40%. Two largest Indian tire companies within 10–15 km of Dahej plant

15K–17K MTPA; revenue potential ₹300–400 Cr; EBITDA margin 11–12%. Consolidated company margins will improve via operating leverage

No real challenges. Already seeding market; product grade not difficult given zinc oxide expertise. Approvals 1–3 months vs. tire 5 years

Non-tire targeted; higher margin accretive (few competitors, solving customer problems). Niche products, sticky once adopted. Export potential for ZRA. Long ramp but sticky customer retention

80% is achievable capacity, not installed capacity. Room to ramp via debottlenecking and efficiency gains. Can meet customer demand

Dahej moved from H1 to Q3, hence conservative 50–60% estimate. Margins improved due to stronger product development and higher-value products expected

Yes. Supply chain disruptions pushed customers to rely on established players with financial strength and global reach. JGC benefited from customer confidence during tight supply

Direct to customer strategy; expect ~90% of new sales direct. Mirrors tire model

15K–17K is purely zinc oxide. Zinc sulphate not included in Dahej Phase 1 expansion

<5% of sales (est. 5–6%). South India market attractive (few large players). Dahej will supply via byproduct circularity; Western India expansion planned

India structurally doing well; auto sector strong; demand scenario favorable. Expect momentum to continue through year

Expect margins to remain this year, then inch up in following years as Gujarat comes online and becomes higher-margin business on standalone basis

R&D critical; ZRA, TUR, new patent pipeline result from R&D. Differentiated products are sticky with customers. Strengthening R&D team; focus increased in last 1–2 years

Backed by ATMA data (PV +26.6%, 2W +16.5%, CV +16.48%, 3W +11% in Q1); tire capex ₹25K+ Cr announced; OEM+replacement demand robust

Contingent on Nov 2026 commissioning and ramp trajectory (50–60% FY28 utilization). Non-rubber approvals underway but volume ramp uncertain

Pre-Dahej period; margin drivers: higher-value product orders, specialized applications, small inventory gains (though one-off element not quantified)

Predicated on Dahej ramp (50–60% → 70–80% utilization), new products (ZRA, LabPure, patent-pending chemical), and non-rubber penetration in ceramics/pharma/specialty chemicals

Announced project; Phase 1 15K–17K MTPA targeting Nov 2026 commissioning; Phase 2 expansion to follow once 70–80% utilization achieved

CFO to provide exact capex offline. Utilities/capabilities built over years, hence phased spend; lower capex per ton than greenfield

Consistent target across all capex; supported by prior execution and current margin profile

Nov 2026 commissioning is tight; civil work advanced but equipment installation underway. Delay would reset 50–60% FY28 utilization and 14–15% margin path by 6–12 months, materially impacting FY28–29 guidance

CFO claims 'neutral to zinc prices' but zinc +6–7% QoQ drove realizations higher; Q1 margin gains partly inventory-driven. If zinc crashes or commodity prices normalize, realized prices and inventory gains evaporate, risking margin compression to <11%

Tire & rubber ~82% of revenue; supplies all Indian tire majors + 9/10 global tier-1 companies. Single-industry downturn (EV disruption, demand shock, OEM capex pullback) would materially impact cash flows and capex payback assumptions

Management guided 14–15% EBITDA by FY29 partly on back of new specialized products. If adoption is slower, approvals extended, or margins lower-than-expected (vs. claimed 'higher-margin accretive'), margin target would slip

Last quarter (geopolitical conflict) impacted Zinc Dross (primary raw material) global supply chains. Management mitigated through scale/relationships but further escalation could disrupt supply or spike input costs despite claimed neutrality